On July 21, Oklo rose 8.04% in after-hours trading to $47.79/share, with turnover of $30.37 million, extending its 5.11% intraday gain. The rally was driven by a convergence of company-specific milestones and broad nuclear sector momentum.

On the company front, Oklo's Groves Isotope Test Reactor in Texas received approval of the documented safety analysis from the U.S. Department of Energy, representing the facility's final safety basis. The approval included technical analysis of potential hazards, safety controls, and operating requirements needed to support safe startup. Only two steps remain — readiness review and startup approval — before the facility is authorized to receive and load nuclear fuel, conduct startup testing, and proceed toward first criticality. Oklo is targeting first criticality within July.

At the industry level, the nuclear power sector is experiencing triple resonance from uranium fuel price increases, capital expansion, and accelerating demand growth, lifting the broader sector. The overlap of this sector-wide momentum with Oklo's near-term commercialization milestone amplified buying interest.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)